Calidi Biotherapeutics, Inc. Increase (Decrease) in Accounts Receivable
Calidi Biotherapeutics, Inc. (CLDI) reported Increase (Decrease) in Accounts Receivable of -$15.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $870.00.
| Period end | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|
| 2026-06-30 | -$15.00K 10-Q · filed 2026-08-13 | |
| 2022-12-31 | $870.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |